The combined detection test for Alzheimer's disease (AD) and traumatic brain injury (TBI), based on the independently developed patented biomarker detection technology, has constructed a multi-dimensional blood diagnosis system covering the whole course of neurodegenerative diseases. This product breaks through the limitations of traditional imaging techniques such as radiation exposure, the strong invasiveness of cerebrospinal fluid testing, and the high subjectivity of scale evaluation. Through a high-sensitivity chemiluminescence platform, it can simultaneously detect multiple core biomarkers with one tube of blood, and it has the advantages of high throughput, high precision, and low cost.